Akman Stella H, Pfeil Johanna M, Stahl Andreas, Ehlers Stephanie, Böhne Carolin, Bohnhorst Bettina, Framme Carsten, Brockmann Dorothee, Bajor Anna, Jacobsen Christina, Hufendiek Karsten, Pielen Amelie
Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Str., 17475, Greifswald, Deutschland.
Ophthalmologe. 2022 May;119(5):497-505. doi: 10.1007/s00347-021-01528-9. Epub 2021 Nov 22.
The Retina.net ROP registry documents data of preterm infants developing stages of retinopathy of prematurity (ROP) that need ROP treatment. The aim of this analysis was to investigate data regarding epidemiology, therapy and changes over time (15 years) in a single participating center (Hannover Medical School, MHH).
Analysis of data of infants treated for ROP at a single center over time (birth 2001-2016, ROP treatment in 2002-2017).
Overall, 65 infants were treated (23 female). In 11 infants (16.9%) ROP screening was conducted externally and infants were transferred to the MHH for ROP treatment. Between 2006 and 2016, incidence of ROP requiring treatment among infants screened for the development of ROP was 4.1%. Mean gestational age was 25.7 weeks (standard deviation, SD 1.8), mean birth weight 763 g (SD 235), postmenstrual age at treatment 38.2 weeks (SD 3.2), postnatal age 12.4 weeks (SD 3.2). There was no significant change in parameters over time. ROP zone II, stage 3+ was most frequently treated (57 eyes of 31 infants). 58 infants were treated with laser (114 eyes), 7 infants were treated with anti-VEGF (bevacizumab, bilateral, 14 eyes) from 2014 onwards. Retreatment due to recurrence of ROP was necessary in one infant after initial laser coagulation. Infants with ROP requiring treatment often presented with neonatal comorbidities, ventilation in more than 90%, bronchopulmonary dysplasia, and received transfusions.
This is the first monocentric analysis over 15 years originating from the Retina.net ROP registry. In this cohort we see a change in ROP therapy from laser coagulation to anti-VEGF (bevacizumab) from 2014 onwards, demographic data and treatment parameters remained relatively stable over time.
视网膜网ROP登记处记录了患有需要ROP治疗的早产儿视网膜病变（ROP）各阶段的数据。本分析的目的是调查单个参与中心（汉诺威医学院，MHH）关于流行病学、治疗及随时间（15年）变化的数据。
分析单个中心随时间（2001年出生至2016年，2002年至2017年进行ROP治疗）接受ROP治疗的婴儿的数据。
总体而言，65名婴儿接受了治疗（23名女性）。11名婴儿（16.9%）在外部进行了ROP筛查，并被转至MHH接受ROP治疗。2006年至2016年期间，在接受ROP发生筛查的婴儿中，需要治疗的ROP发生率为4.1%。平均胎龄为25.7周（标准差，SD 1.8），平均出生体重763克（SD 235），治疗时的月经后年龄为38.2周（SD 3.2），出生后年龄为12.4周（SD 3.2）。随着时间推移，各项参数无显著变化。II区3+期ROP是最常接受治疗的（31名婴儿的57只眼）。58名婴儿接受了激光治疗（114只眼），自2014年起，7名婴儿接受了抗VEGF治疗（贝伐单抗，双侧，14只眼）。1名婴儿在初次激光凝固治疗后因ROP复发而需要再次治疗。需要治疗的ROP婴儿常伴有新生儿合并症，超过90%需要通气，患有支气管肺发育不良，并接受输血。
这是来自视网膜网ROP登记处的首次为期15年的单中心分析。在该队列中，我们看到自2014年起ROP治疗从激光凝固转变为抗VEGF（贝伐单抗），人口统计学数据和治疗参数随时间保持相对稳定。
